Related Experiment Video

Updated: Jun 3, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers

Rita Nanda1

  • 1Department of Medicine, The University of Chicago, Chicago, IL 60637-1470, USA. rnanda@medicine.bsd.uchicago.edu

Seminars in Oncology
|March 23, 2011
PubMed

Insights

Triple-negative breast cancer (TNBC) remains a challenge, with poor outcomes despite advances in other breast cancer types. Understanding TNBC and BRCA1-associated breast cancer biology offers hope for improved treatments.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Breast cancer is a heterogeneous disease with varying tumor biology and treatment responses.
  • Molecular profiling has enhanced understanding of breast cancer complexity.
  • Hormone receptor (HR) and HER2-positive breast cancers have seen treatment advances, but triple-negative breast cancer (TNBC) outcomes remain poor.

Purpose of the Study:

  • To review the clinicopathological features of TNBC.
  • To discuss current therapeutic options for TNBC.
  • To highlight ongoing research efforts for TNBC and BRCA1-associated breast cancer.

Main Methods:

  • Literature review of clinicopathological features.
  • Analysis of current therapeutic strategies.
  • Synthesis of ongoing research in TNBC and BRCA1-associated breast cancer.

Main Results:

  • TNBC is characterized by estrogen receptor (ER)-, progesterone receptor (PR)-, and HER2-negative status.
  • BRCA1-associated breast cancer shares biological similarities with sporadic TNBC.
  • Current treatment options for TNBC are limited, underscoring the need for further research.

Conclusions:

  • A deeper understanding of the shared biology between BRCA1-associated breast cancer and sporadic TNBC is crucial.
  • Targeting shared pathways may lead to novel therapeutic strategies for aggressive TNBC.
  • Continued research is essential to improve outcomes for patients with TNBC.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...